Singulair 10mg 28 chewable tablets — Made in Great Britain — Free Delivery

Brand: MERCK
Product Code: Singulair
Availability: In Stock

$31.12

Description

Product description

Singular® tablets are used for the following indications:

as an additional treatment for bronchial asthma in patients with persistent mild to moderate asthma, which is insufficiently controlled by inhaled corticosteroids, as well as in case of insufficient clinical control of asthma using short-acting β-adrenergic receptor agonists, which are used if necessary (in patients with asthma taking “ Singular®, this preparation also relieves symptoms of seasonal allergic rhinitis);
prevention of asthma, the dominant component of which is exercise-induced bronchospasm;
relief of symptoms of seasonal and perennial allergic rhinitis.

Compound

The active ingredient is montelukast (one coated tablet contains montelukast sodium 10.4 mg (equivalent to montelukast 10 mg)).

Excipients: hydroxypropyl cellulose, microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate.

Tablet shell: hydroxypropyl cellulose, methyl hydroxypropyl cellulose, titanium dioxide (E 171), iron oxide red (E172), iron oxide yellow (E 172), carnauba wax.

Contraindications

hypersensitivity to the components of the preparation;

age up to 15 years.

Mode of application

The dose for patients (over 15 years old) with asthma or asthma and concomitant seasonal allergic rhinitis is 10 mg (one tablet) per day, in the evening. To relieve the symptoms of allergic rhinitis, the time of admission is selected individually.

General recommendations. The therapeutic effect of the preparation "Singular®" on the parameters of asthma control occurs within one day. The preparation can be used regardless of food intake. Patients should be advised to continue taking Singulair® even if asthma control is achieved, as well as during periods of asthma exacerbation. "Singular®" should not be used simultaneously with medicinal products containing the active ingredient montelukast.

Application of the preparation "Singular®" depending on other asthma treatment. Singular® can be added to an existing asthma treatment.

Inhaled corticosteroids. The preparation "Singular®" can be used as an additional treatment for patients in whom inhaled corticosteroids, together with short-acting β-agonists, used if necessary, do not provide satisfactory clinical control of the disease.

The Singular® preparation should not drastically change inhaled corticosteroids.

Application features

Pregnant

The preparation "Singular®" should be used during pregnancy only when clearly necessary.

Singular® can be used during breastfeeding only if it is considered absolutely necessary.

Children

Applied to children over 15 years of age.

Drivers

It is not expected that montelukast will affect the patient's ability to drive vehicles or other machinery. However, drowsiness or dizziness has been reported very rarely.

Overdose

There is no special information on the treatment of an overdose with the preparation "Singular®". In studies of chronic asthma, montelukast was prescribed in doses up to 200 mg / day to adult patients for 22 weeks, and in short-term studies - up to 900 mg / day for about one week, while clinically significant adverse reactions did not occur.

In post-marketing use and in clinical trials, there have been reports of acute overdose of the preparation "Singular®". These included the administration of the preparation in adults and children in doses exceeding 1000 mg (approximately 61 mg / kg in a child aged 42 months). The obtained clinical and laboratory data were consistent with the safety profile in adult patients and children. In most cases of overdose, no adverse reactions were reported. The most common adverse reactions were observed, which corresponded to the safety profile of the preparation "Singular" and included: abdominal pain, drowsiness, thirst, headache, vomiting and psychomotor hyperactivity.

It is not known whether montelukast is excreted by peritoneal dialysis or hemodialysis.

Side effects

In clinical studies, the following adverse reactions were reported frequently (≥ 1/100 to <1/10) in patients treated with montelukast, and also more frequently than in patients receiving placebo.

From the side of the nervous system - headache.

From the gastrointestinal tract (GIT) - abdominal pain.

Storage conditions

Store in its original packaging at a temperature not exceeding 30 ° C, out of the reach of children.

Shelf life is 3 years.

0 reviews

There are no reviews for this product.